A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma

BACKGROUND: There is an urgent need for effective treatments against glioblastoma (GBM). In this trial, we investigated the efficacy and safety of an adoptive cell-based immunotherapy. METHODS: Patients with newly diagnosed GBM were recruited at 4 study sites in Sweden. The patients were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Werlenius, Katja, Stragliotto, Giuseppe, Strandeus, Michael, Blomstrand, Malin, Carén, Helena, Jakola, Asgeir S, Rydenhag, Bertil, Dyregaard, Dorte, Dzhandzhugazyan, Karine N, Kirkin, Alexei F, Raida, Martin K, Smits, Anja, Kinhult, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577524/
https://www.ncbi.nlm.nih.gov/pubmed/34765977
http://dx.doi.org/10.1093/noajnl/vdab156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577524/
https://www.ncbi.nlm.nih.gov/pubmed/34765977
http://dx.doi.org/10.1093/noajnl/vdab156

Ejemplares similares